In this study, we want to find out if a combination of 3 different study drugs (Cabozantinib, Ipilimumab, and Nivolumab) will affect the progression of Soft Tissue Sarcoma.
You will be randomized to a combination of drugs. You will receive the drugs via IV. You will receive treatment until disease progression. You will then be contacted 30 days after your last dose to evaluate any adverse events.
Study Drug
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA
Mark Woodcock
LCCC - Clinical Trials
Clinical or Medical
Interventional
Cancer (Sarcoma (bone and soft tissue))
24-0298